期刊
BLOOD
卷 120, 期 6, 页码 1165-1174出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-05-378943
关键词
-
类别
资金
- National Institutes of Health [CA36401, CA21765, GM92666]
- American Lebanese Syrian Associated Charities
- Sigma-Tau Pharmaceuticals
Improved supportive care, more precise risk stratification, and personalized chemotherapy based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood acute lymphoblastic leukemia to near 90%. Further increase in cure rate can be expected from the discovery of additional recurrent molecular lesions, coupled with the development of novel targeted treatment through high-throughput genomics and innovative drug-screening systems. We discuss specific areas of research that promise to further refine current treatment and to improve the cure rate and quality of life of the patients. (Blood. 2012;120(6):1165-1174)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据